Aclaris Financial Statements From 2010 to 2025

Stocks . USA . 
Stock . Aclaris Therapeutics
ACRS Stock  USD 1.58  0.02  1.28%   
Aclaris Therapeutics financial statements provide useful quarterly and yearly information to potential Aclaris Therapeutics investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Aclaris Therapeutics financial statements helps investors assess Aclaris Therapeutics' valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Aclaris Therapeutics' valuation are summarized below:
Gross Profit
-30.3 M
Market Capitalization
170.9 M
Enterprise Value Revenue
2.817
Revenue
18.7 M
Earnings Share
(1.71)
There are over one hundred nineteen available fundamental signals for Aclaris Therapeutics, which can be analyzed over time and compared to other ratios. All traders should validate Aclaris Therapeutics' prevailing fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction. Market Cap is likely to gain to about 382 M in 2025. Enterprise Value is likely to gain to about 327.7 M in 2025

Aclaris Therapeutics Total Revenue

10.9 Million

Check Aclaris Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Aclaris Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 766.6 K, Interest Expense of 3.2 M or Selling General Administrative of 21.5 M, as well as many indicators such as Price To Sales Ratio of 9.73, Dividend Yield of 0.0 or PTB Ratio of 0.7. Aclaris financial statements analysis is a perfect complement when working with Aclaris Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Aclaris Therapeutics Correlation against competitors.
For more information on how to buy Aclaris Stock please use our How to Invest in Aclaris Therapeutics guide.

Aclaris Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets175.4 M220.3 M133.2 M
Slightly volatile
Other Current Liabilities24.2 M23 M6.6 M
Slightly volatile
Total Current Liabilities17.8 M31.6 M13.3 M
Slightly volatile
Other Liabilities40.4 M38.5 M12.1 M
Slightly volatile
Property Plant And Equipment Net1.6 M1 M1.2 M
Slightly volatile
Accounts Payable7.1 M4.7 M5.3 M
Slightly volatile
Cash23.3 M24.6 M37.8 M
Pretty Stable
Non Current Assets Total99.1 M94.4 M31.1 M
Slightly volatile
Cash And Short Term Investments136.6 M113.6 M104.1 M
Slightly volatile
Common Stock Shares Outstanding42.4 M77.3 M33.6 M
Slightly volatile
Short Term Investments96.4 M89 M72.4 M
Slightly volatile
Liabilities And Stockholders Equity175.4 M220.3 M133.2 M
Slightly volatile
Non Current Liabilities Total23.1 M33.2 M20.2 M
Very volatile
Other Current Assets7.7 M12 M5.8 M
Slightly volatile
Other Stockholder Equity551.3 M1.1 B410.4 M
Slightly volatile
Total Liabilities39 M64.8 M33.4 M
Slightly volatile
Property Plant And Equipment Gross3.1 M5.8 M2.3 M
Slightly volatile
Total Current Assets139.1 M126 M106 M
Slightly volatile
Property Plant Equipment1.9 M1.3 M1.3 M
Slightly volatile
Other Assets1.9 M2 M20.7 M
Pretty Stable
Net Receivables302.1 K318 K591 K
Pretty Stable
Capital Surpluse553.9 M1 B447.1 M
Slightly volatile
Non Current Liabilities Other13.2 M13.1 M7.7 M
Slightly volatile
Short and Long Term Debt Total364.2 K383.4 K2.9 M
Very volatile
Capital Lease Obligations594.9 K489.9 K366.6 K
Slightly volatile
Net Invested Capital129.6 M155.6 M187.7 M
Slightly volatile
Short and Long Term Debt113.6 K127.8 K139.3 K
Slightly volatile
Net Working Capital102.8 M94.4 M152.7 M
Slightly volatile
Short Term Debt906.1 K489.9 K509.7 K
Slightly volatile
Long Term Debt Total10.8 M9.6 M20.8 M
Slightly volatile
Current Deferred Revenue3.7 M3.9 M8.7 M
Pretty Stable

Aclaris Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization766.6 K807 K2.8 M
Pretty Stable
Selling General Administrative21.5 M22.2 M16.3 M
Slightly volatile
Other Operating Expenses85.5 M160.7 M64.7 M
Slightly volatile
Research Development46.9 M33.6 M35.6 M
Slightly volatile
Total Operating Expenses80.5 M157.9 M60.9 M
Slightly volatile
Interest Income83.2 K93.6 K102 K
Slightly volatile
Preferred Stock And Other Adjustments2.1 M2.3 M2.5 M
Slightly volatile
Reconciled Depreciation1.3 M807 K1.1 M
Pretty Stable
Selling And Marketing Expenses242 K254.7 K27.1 M
Slightly volatile
Non Recurring14.8 M16.7 M18.2 M
Slightly volatile

Aclaris Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow30 M39.9 M25.9 M
Slightly volatile
Depreciation1.3 M807 K932.5 K
Slightly volatile
End Period Cash Flow30.5 M24.6 M24.5 M
Slightly volatile
Stock Based Compensation12.9 M10.9 M8.9 M
Slightly volatile
Change To Netincome22 M22.7 M15.3 M
Slightly volatile
Change To Inventory730.5 K695.8 K335.6 K
Slightly volatile
Issuance Of Capital Stock81.8 M74.9 M87.7 M
Pretty Stable

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio9.7310.2402222
Slightly volatile
Days Sales Outstanding5.896.200363.3938
Slightly volatile
Stock Based Compensation To Revenue0.550.57995.0317
Slightly volatile
Capex To Depreciation0.140.149911.7877
Slightly volatile
EV To Sales8.488.9277159
Slightly volatile
Payables Turnover0.520.59530.4759
Slightly volatile
Sales General And Administrative To Revenue1.131.186111.0851
Slightly volatile
Research And Ddevelopement To Revenue1.71.794114.4606
Slightly volatile
Capex To Revenue0.00610.00650.411
Slightly volatile
Cash Per Share1.41.46963.7914
Very volatile
Days Payables Outstanding5826134.2 K
Slightly volatile
Income Quality0.140.1520.7379
Slightly volatile
Intangibles To Total Assets0.00150.00160.0884
Slightly volatile
Net Debt To EBITDA0.450.47511.0863
Slightly volatile
Current Ratio3.793.986319.1432
Slightly volatile
Receivables Turnover61.8158.867922.3862
Slightly volatile
Debt To Equity0.0030.00310.0294
Pretty Stable
Capex Per Share0.00150.00160.0288
Slightly volatile
Revenue Per Share0.190.24220.156
Slightly volatile
Interest Debt Per Share0.00670.0070.0851
Very volatile
Debt To Assets0.00240.00250.0183
Pretty Stable
Days Of Payables Outstanding5826134.2 K
Slightly volatile
Ebt Per Ebit0.820.93051.0014
Very volatile
Long Term Debt To Capitalization0.140.20.1588
Slightly volatile
Total Debt To Capitalization0.0030.00310.024
Pretty Stable
Debt Equity Ratio0.0030.00310.0294
Pretty Stable
Quick Ratio3.793.986319.2869
Slightly volatile
Net Income Per E B T1.191.151.0574
Slightly volatile
Cash Ratio0.740.77769.5533
Slightly volatile
Days Of Sales Outstanding5.896.200363.3938
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio1.121.0061.0329
Pretty Stable
Fixed Asset Turnover19.518.57146.4826
Slightly volatile
Debt Ratio0.00240.00250.0183
Pretty Stable
Price Sales Ratio9.7310.2402222
Slightly volatile
Asset Turnover0.05650.0850.0419
Slightly volatile
Gross Profit Margin0.890.85090.3685
Slightly volatile

Aclaris Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap382 M191.7 M275.2 M
Pretty Stable
Enterprise Value327.7 M167.1 M238.5 M
Pretty Stable

Aclaris Fundamental Market Drivers

Cash And Short Term Investments113.6 M

Aclaris Upcoming Events

22nd of February 2024
Upcoming Quarterly Report
View
13th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
22nd of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Aclaris Therapeutics Financial Statements

Aclaris Therapeutics shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Aclaris Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Aclaris Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Aclaris Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue3.9 M3.7 M
Total Revenue18.7 M10.9 M
Cost Of Revenue2.8 M5.5 M
Stock Based Compensation To Revenue 0.58  0.55 
Sales General And Administrative To Revenue 1.19  1.13 
Research And Ddevelopement To Revenue 1.79  1.70 
Capex To Revenue 0.01  0.01 
Revenue Per Share 0.24  0.19 
Ebit Per Revenue(7.58)(7.96)

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Aclaris Stock Analysis

When running Aclaris Therapeutics' price analysis, check to measure Aclaris Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aclaris Therapeutics is operating at the current time. Most of Aclaris Therapeutics' value examination focuses on studying past and present price action to predict the probability of Aclaris Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aclaris Therapeutics' price. Additionally, you may evaluate how the addition of Aclaris Therapeutics to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY